Lanreotide Acetate
Q2 ASP Report
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
MARCH 2024
Aria analytics
Aria is dedicated to enhancing value for our members through cutting-edge analytics and business intelligence solutions. With this objective, our team has compiled a report to assist members in understanding the product landscape, visualizing ASP trends, and anticipating future ASPs for key products.
Our goal is to empower members with clear insights, enabling well-informed purchasing decisions and the development of sustainable, long-term strategies.
The
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
no
warranties regarding, the content, accuracy
completeness of the
the
property rights to any pharmaceutical product
content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes
representations nor
or
information presented. Aria GPO does not own
intellectual
mentioned herein.
Table of contents
• Product comparison
• Average Sales Prices Q1 2024 & Q2 2024
• Reimbursement information for Q2 2024
• Historical ASPs
• Average Change of ASP
• WAC vs. Initial ASPs
• ASP Percent Change from WAC
• Aria ASP predictive model
The content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes no representations nor warranties regarding, the content, accuracy or completeness of the information presented. Aria GPO does not own the intellectual property rights to any pharmaceutical product mentioned herein.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product comparison
Somatuline Depot (Ipsen)
Lanreotide Acetate (Cipla)
Injection: single-dose prefilled syringe
Injection: single-dose prefilled syringe
60 mg/0.2mL, 90 mg/0.3mL, 120 mg/0.5mL
Acromegaly, GEP-NETs, Carcinoid Syndrome Yes
Acromegaly, GEP-NETs
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product Strength & Dosage Treatment Cold Chain
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product WAC Previous ASP New ASP % Change Innovator Somatuline Depot (Ipsen) $9,562.00 $5,484.11 $6,373.58 16.22% 505(b)(2) Lanreotide Acetate (Cipla) $8,892.66 $5,521.92 $4,983.85 -9.74% 16.22% -9.74% $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 Previous ASP Current ASP ASP Change Somatuline Depot (Ipsen) Lanreotide Acetate (Cipla)
Average Sales Prices Q1 2024 & Q2 2024
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product Launch Date HCPCS WAC ASP Anticipated Medicare Reimbursement* Innovator Somatuline Depot (Ipsen) 1/31/2009 J1930 $9,562.00 $6,373.58 $6,647.90 505(b)(2) Lanreotide Acetate (Cipla) 2/28/2022 J1932 $8,892.66 $4,983.85 $5,198.35
Medicare
Reimbursement information for Q2 2024
*Includes
sequestration
Historical ASPs
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 $8,000 $9,000 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Somatuline Depot (Ipsen) Lanreotide Acetate (Cipla)
Average Change of ASP
This graph showcases the cumulative average change in the average sales price (ASP) for the Lanreotide family, tracking changes from the launch of biosimilars to each quarter's ASP. It highlights the evolution of ASP over the product's lifecycle and the fluctuating rate of change, providing a concise overview of pricing dynamics.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-6% -5% -4% -3% -2% -1% 0% 1% 2% 3% 4% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Somatuline Depot (Ipsen) Lanreotide Acetate (Cipla)
WAC* vs. Initial ASPs
*Refers to the WAC when the first ASP was released
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-68.22% -22.49% -67.95% -23.14% -65.59% -22.99% $0 $2,000 $4,000 $6,000 $8,000 $10,000 $12,000
Somatuline Depot (Ipsen)
Lanreotide Acetate (Cipla)
WAC First ASP Second ASP Third ASP
ASP Percent Change from WAC*
*Refers to the WAC when the first ASP was released
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-50% -45% -40% -35% -30% -25% -20% -15% -10% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021.1 Q2 2021 Q3 2021 Q4 2021 Q1 2021 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Somatuline Depot (Ipsen) Lanreotide Acetate (Cipla)
Aria ASP predictive model
In line with Aria's goal to provide key insights to our members, our analytics team has developed a proprietary predictive ASP model for the Lanreotide product family.
Q12019Q22019Q32019Q42019Q12020Q22020Q32020Q42020Q12021Q22021Q32021Q42021Q12022Q22022Q32022Q42022Q12023Q22023Q32023Q42023Q12024Q22024
Q32024Predicted
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 $8,000 $9,000
Somatuline Depot (Ipsen)
Lanreotide Acetate (Cipla)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential. Thank you. www.ariagpo.com info@ariagpo.com